Genenta Science SPA
NASDAQ:GNTA

Watchlist Manager
Genenta Science SPA Logo
Genenta Science SPA
NASDAQ:GNTA
Watchlist
Price: 5.01 USD -6.53% Market Closed
Market Cap: 91.6m USD
Have any thoughts about
Genenta Science SPA?
Write Note

Genenta Science SPA
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Genenta Science SPA
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
Genenta Science SPA
NASDAQ:GNTA
Capital Expenditures
-€13.8k
CAGR 3-Years
12%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Philogen SpA
MIL:PHIL
Capital Expenditures
-€5.9m
CAGR 3-Years
-17%
CAGR 5-Years
-52%
CAGR 10-Years
N/A
Ulisse Biomed Spa
MIL:UBM
Capital Expenditures
-€98.6k
CAGR 3-Years
3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Genenta Science SPA
Glance View

Market Cap
91.6m USD
Industry
Biotechnology

Genenta Science SpA engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors. The company is headquartered in Milan, Milano and currently employs 4 full-time employees. The company went IPO on 2021-12-15. The firm focuses on the development of lentivirus-based gene and cell therapies in cancer. The company uses gene-based cytokine delivery to activate the immune system within the tumor providing the anti-tumor response. The firm not only operates locally but also is present in global markets, including the United States.

GNTA Intrinsic Value
1.07 USD
Overvaluation 79%
Intrinsic Value
Price

See Also

What is Genenta Science SPA's Capital Expenditures?
Capital Expenditures
-13.8k EUR

Based on the financial report for Dec 31, 2023, Genenta Science SPA's Capital Expenditures amounts to -13.8k EUR.

What is Genenta Science SPA's Capital Expenditures growth rate?
Capital Expenditures CAGR 3Y
12%

Over the last year, the Capital Expenditures growth was 54%. The average annual Capital Expenditures growth rates for Genenta Science SPA have been 12% over the past three years .

Back to Top